Table 4.
IC50, Combination Index (CI) and Dose Reduction index (DRI) values of free RSV, free PMT and free RSV/PMT co-solvent compared to the prepared nano-formulations on MDA-MB-231 breast cancer cell line at the concentration of 0–60 μg/ml after 24 h
| Drug/combo | CI value | Total IC50 of combination | Dose RSV | Dose PMT | DRI of RSV | DRI of PMT |
|---|---|---|---|---|---|---|
| RSV | – | – | 25.28 | – | – | – |
| PMT | – | – | – | 21.06 | – | – |
| Blank NPs | – | – | – | – | – | 28,128 |
| RSV/PMT | 1.04 | 17.11 | 9.65 | 7.54 | 2.61 | 2.79 |
| F1 [RSV/PMT-BSA NPs] | 0.975 | 14.25 | 8.03 | 6.28 | 3.14 | 3.35 |
| F2 [RSV/PMT-BSA-QDs NPs] | 0.931 | 13.24 | 7.46 | 5.83 | 3.38 | 3.60 |
| F3 [Mann-targeted RSV/PMT-BSA-QDs NPs] | 0.873 | 10.96 | 6.18 | 4.83 | 4.08 | 4.35 |
| F4 [Mann-targeted RSV/PMT-BSA NPs] | 0.910 | 11.13 | 6.27 | 4.90 | 4.02 | 4.29 |